Tags

Type your tag names separated by a space and hit enter

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.
Dig Dis Sci 2008; 53(1):169-74DD

Abstract

PURPOSE

Previous studies demonstrate improvement in IBS after antibiotic therapy, with the greatest efficacy seen with the antibiotic, rifaximin. The purpose of this study was to compare the efficacy of rifaximin in both the treatment and retreatment of IBS.

METHODS

A retrospective chart review was conducted on Rome I-positive IBS patients. Charts were reviewed to evaluate all antibiotic treatments (rifaximin, neomycin, doxycycline, amoxicillin/clavulanate, and ciprofloxacin), even those predating 1 July 2004. Data collection included symptoms, breath test results (pre- and post-treatment), antibiotics used, and clinical response to individual antibiotic treatments before and after rifaximin availability in the USA.

RESULTS

Out of 98 eligible charts, 84 patients received one course of rifaximin. Fifty of these (60%) had a follow-up breath test. Among these, 31 (62%) were clinical responders and 19 (38%) were nonresponders. Of 31 responders, 25 (81%) had a normal follow-up breath test compared with only 3 of the 19 nonresponders (16%) (P < 0.001). Of participants given rifaximin, 69% (58 out of 84) had a clinical response compared with only 38% (9 out of 24) with neomycin (P < 0.01) and 44% (27 out of 61) with all non-rifaximin antibiotics (P < 0.01). Rifaximin was used as retreatment on 16 occasions, and all patients improved.

CONCLUSIONS

Rifaximin is more effective than other antibiotics in the treatment and retreatment of IBS.

Authors+Show Affiliations

GI Motility Program, GI Motility Laboratory, Cedars-Sinai Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17520365

Citation

Yang, Janet, et al. "Rifaximin Versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS." Digestive Diseases and Sciences, vol. 53, no. 1, 2008, pp. 169-74.
Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169-74.
Yang, J., Lee, H. R., Low, K., Chatterjee, S., & Pimentel, M. (2008). Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Digestive Diseases and Sciences, 53(1), pp. 169-74.
Yang J, et al. Rifaximin Versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. Dig Dis Sci. 2008;53(1):169-74. PubMed PMID: 17520365.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. AU - Yang,Janet, AU - Lee,Hyo-Rang, AU - Low,Kimberly, AU - Chatterjee,Soumya, AU - Pimentel,Mark, Y1 - 2007/05/23/ PY - 2006/11/13/received PY - 2007/04/05/accepted PY - 2007/5/24/pubmed PY - 2008/2/20/medline PY - 2007/5/24/entrez SP - 169 EP - 74 JF - Digestive diseases and sciences JO - Dig. Dis. Sci. VL - 53 IS - 1 N2 - PURPOSE: Previous studies demonstrate improvement in IBS after antibiotic therapy, with the greatest efficacy seen with the antibiotic, rifaximin. The purpose of this study was to compare the efficacy of rifaximin in both the treatment and retreatment of IBS. METHODS: A retrospective chart review was conducted on Rome I-positive IBS patients. Charts were reviewed to evaluate all antibiotic treatments (rifaximin, neomycin, doxycycline, amoxicillin/clavulanate, and ciprofloxacin), even those predating 1 July 2004. Data collection included symptoms, breath test results (pre- and post-treatment), antibiotics used, and clinical response to individual antibiotic treatments before and after rifaximin availability in the USA. RESULTS: Out of 98 eligible charts, 84 patients received one course of rifaximin. Fifty of these (60%) had a follow-up breath test. Among these, 31 (62%) were clinical responders and 19 (38%) were nonresponders. Of 31 responders, 25 (81%) had a normal follow-up breath test compared with only 3 of the 19 nonresponders (16%) (P < 0.001). Of participants given rifaximin, 69% (58 out of 84) had a clinical response compared with only 38% (9 out of 24) with neomycin (P < 0.01) and 44% (27 out of 61) with all non-rifaximin antibiotics (P < 0.01). Rifaximin was used as retreatment on 16 occasions, and all patients improved. CONCLUSIONS: Rifaximin is more effective than other antibiotics in the treatment and retreatment of IBS. SN - 0163-2116 UR - https://www.unboundmedicine.com/medline/citation/17520365/full_citation L2 - https://doi.org/10.1007/s10620-007-9839-8 DB - PRIME DP - Unbound Medicine ER -